While this has also been indicated by previous studies, our data are the first to indicate more clearly how MS patients may benefit from approaches that promote specific physiological mechanisms for immunosuppression under conditions of chronic inflammation, such as induction of NLRP12, S100A8, and S100A9. Here, S100A9 is linked to myeloid sarcoma.